<DOC>
	<DOC>NCT02684760</DOC>
	<brief_summary>PF-06651600 is being developed for treatment of inflammatory bowel disease. This study will test the bioavailability of a solid dose formulation of PF-06651600 compared to an oral solution formulation under fasting conditions and the effect of a high fat meal on the bioavailability of the solid dose formulation of PF-06651600 in healthy subjects. Safety and tolerability of the tablet and oral solution formulations of PF-06651600 will be assessed under fasting and fed conditions.</brief_summary>
	<brief_title>Bioavailability Study Of PF-06651600 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male/female subjects between 18 and 55 years old, inclusive. Females must be of nonchild bearing potential. BMI of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Prior history of chicken pox. Evidence of personally signed and dated informed consent document. Willing and able to comply with scheduled visits, treatment plan, lab tests and other study procedures. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, GI, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males. Screening blood pressure &gt;140/90 mm Hg. Screening laboratory abnormalities as defined by the protocol. Unwilling or unable to comply with the Lifestyle Guidelines as defined by the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>